Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
Stable expression over 15 generations with rapid cell line development in just 3 months. Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
Predicted to enable calmodulin binding activity and protein kinase A binding activity. Acts upstream of or within several processes, including Kupffer's vesicle development; bleb assembly; and negative regulation of Rho protein signal transduction. Located in perinuclear region of cytoplasm. Is expressed in several structures, including cardiovascular system; germ ring; mesoderm; nervous system; and tail bud. Human ortholog(s) of this gene implicated in chronic kidney disease; colorectal carcinoma; and juvenile myelomonocytic leukemia. Orthologous to human AKAP12 (A-kinase anchoring protein 12). [provided by Alliance of Genome Resources, Feb 2025]